Celltex Therapeutics Corporation   Report issue

For profit Phase 2
Founded: Houston TX United States (2011)

Organization Overview

First Clinical Trial
2020
NCT04170426
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Celltex Therapeutics Corporation

Active Ingredients

Drugs in Phase 2 Trials (1)

autologous adipose-derived mesenchymal stem cells (4 trials)

Drugs in Other Trials (1)

allogeneic adipose derived mesenchymal stem cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2